Fujii K
Cancer Lett. 1983 Jan;17(3):321-5. doi: 10.1016/0304-3835(83)90170-2.
The maximum tolerated dose of 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB) or 4-aminoazobenzene (AB) was administered subcutaneously to pregnant ICR/JCL mice on days 15, 17 and 19 of gestation, or to neonatal mice. All animals were killed at 1 year of age. In the transplacental treatment, 3'-Me-DAB induced neoplastic lesions in liver and lung, but the incidence in mice treated with AB was not significantly different to that of the controls. Following neonatal treatment, mice treated with 3'-Me-DAB or AB developed neoplastic lesions of liver, lung and lymphoreticular tissues.
在妊娠第15、17和19天,将3'-甲基-4-二甲基氨基偶氮苯(3'-Me-DAB)或4-氨基偶氮苯(AB)的最大耐受剂量皮下注射给怀孕的ICR/JCL小鼠,或新生小鼠。所有动物在1岁时处死。在经胎盘治疗中,3'-Me-DAB诱导肝脏和肺部出现肿瘤性病变,但AB治疗组小鼠的发病率与对照组无显著差异。新生小鼠治疗后,用3'-Me-DAB或AB治疗的小鼠出现肝脏、肺部和淋巴网状组织的肿瘤性病变。